Novartis set to buy Avidity Biosciences for more than $10bn
found
a story from Financial Times ✅ › Financial Times
Deal would be biggest acquisition under chief executive Vas Narasimhan
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Avidity Biosciences
since
auto-detected in 2 stories
41 days ago
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports ⊕
found
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.
page 1 of 1